{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kozminsky M"],"funding":["U.S. Department of Defense","A. Alfred Taubman Medical Research Institute","NCI NIH HHS","National Institutes of Health","Prostate Cancer Foundation","NIH HHS","National Science Foundation"],"pagination":["1801254"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6343066"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(2)"],"pubmed_abstract":["Rates of progression and treatment response in advanced prostate cancer are highly variable, necessitating non-invasive methods to assess the molecular characteristics of these tumors in real time. The unique potential of circulating tumor cells (CTCs) to serve as a clinically useful liquid biomarker is due to their ability to inform via both enumeration and RNA expression. A microfluidic graphene oxide-based device (GO Chip) is used to isolate CTCs and CTC clusters from the whole blood of 41 men with metastatic castration-resistant prostate cancer. Additionally, the expression of 96 genes of interest is determined by RT-qPCR. Multivariate analyses are conducted to determine the genes most closely associated with overall survival, PSA progression, and radioclinical progression. A prelimina"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Detection of CTC Clusters and a Dedifferentiated RNA-Expression Survival Signature in Prostate Cancer."],"pmcid":["PMC6343066"],"funding_grant_id":["1DP2OD006672‐01","DGE 1256260","DP2 OD006672","W81XWH‐14‐1‐0287","R33 CA202867","R01 CA208335"],"pubmed_authors":["Azizi E","Fouladdel S","Smith DC","Alva A","Morgan T","Nagrath S","Chung JS","Wang Y","Kozminsky M"],"additional_accession":[]},"is_claimable":false,"name":"Detection of CTC Clusters and a Dedifferentiated RNA-Expression Survival Signature in Prostate Cancer.","description":"Rates of progression and treatment response in advanced prostate cancer are highly variable, necessitating non-invasive methods to assess the molecular characteristics of these tumors in real time. The unique potential of circulating tumor cells (CTCs) to serve as a clinically useful liquid biomarker is due to their ability to inform via both enumeration and RNA expression. A microfluidic graphene oxide-based device (GO Chip) is used to isolate CTCs and CTC clusters from the whole blood of 41 men with metastatic castration-resistant prostate cancer. Additionally, the expression of 96 genes of interest is determined by RT-qPCR. Multivariate analyses are conducted to determine the genes most closely associated with overall survival, PSA progression, and radioclinical progression. A prelimina","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2025-04-04T19:07:34.248Z","creation":"2019-03-26T22:43:46Z"},"accession":"S-EPMC6343066","cross_references":{"pubmed":["30693182"],"doi":["10.1002/advs.201801254"]}}